https://www.oncologynurseadvisor.com Sat, 14 Oct 2023 02:51:30 +0000 en-US hourly 1 https://wordpress.org/?v=6.4.3 https://www.oncologynurseadvisor.com/wp-content/uploads/sites/13/2024/01/cropped-CTA-ONA-HEM-favicon-32x32.png https://www.oncologynurseadvisor.com 32 32 https://www.oncologynurseadvisor.com/home/cancer-types/prostate-cancer/prostate-cancer-progression-intensifying-salvage-treatment-reduces-risk/ Thu, 02 Jun 2022 14:20:00 +0000 https://www.cancertherapyadvisor.com/?p=125357 Short-term androgen deprivation therapy alone or in combination with pelvic lymph node radiotherapy can improve the efficacy of prostate bed radiotherapy. ]]> https://www.oncologynurseadvisor.com/home/cancer-types/gastrointestinal-cancer/rectal-cancer-organ-preservation-feasible-total-neoadjuvant-therapy/ Tue, 24 May 2022 14:00:00 +0000 https://www.oncologynurseadvisor.com/?p=99227 A rectum-preserving strategy may produce outcomes similar to standard resection-based treatment for locally advanced rectal adenocarcinoma.]]> https://www.oncologynurseadvisor.com/home/cancer-types/gastrointestinal-cancer/esophageal-cancer-incidence-on-the-rise-in-middle-aged-adults/ Fri, 20 May 2022 14:00:00 +0000 https://www.oncologynurseadvisor.com/?p=99121 The incidence of esophageal cancer nearly doubled, and this was not due to an increase in screening. ]]> https://www.oncologynurseadvisor.com/home/cancer-types/lung-cancer/lung-cancer-brain-metastasis-immunotherapy-survival-benefit/ Wed, 18 May 2022 14:30:00 +0000 https://www.oncologynurseadvisor.com/?p=99119 Immunotherapy prolonged survival compared with platinum chemotherapy.]]> https://www.oncologynurseadvisor.com/home/cancer-types/lung-cancer/non-small-cell-lung-cancer-durvalumab-oleclumab-monalizumab-show-promise/ Tue, 17 May 2022 14:00:00 +0000 https://www.oncologynurseadvisor.com/?p=99064 Combining either oleclumab or monalizumab with durvalumab provided a progression-free survival benefit over durvalumab alone. ]]> https://www.oncologynurseadvisor.com/home/cancer-types/multiple-myeloma/multiple-myeloma-elotuzumab-does-not-improve-progression-free-survival/ Mon, 16 May 2022 14:00:00 +0000 https://www.oncologynurseadvisor.com/?p=99062 Adding elotuzumab to lenalidomide and dexamethasone did not improve any efficacy outcomes. ]]> https://www.oncologynurseadvisor.com/home/cancer-types/lung-cancer/non-small-cell-lung-cancer-segmentectomy-should-be-standard-early-stage/ Fri, 13 May 2022 14:30:00 +0000 https://www.oncologynurseadvisor.com/?p=98933 Segmentectomy prolonged 5-year overall survival in a phase 3 trial.]]> https://www.oncologynurseadvisor.com/home/cancer-types/lung-cancer/non-small-cell-lung-cancer-blood-tumor-mutational-burden-predict-response-atezolizumab/ Wed, 11 May 2022 14:00:00 +0000 https://www.oncologynurseadvisor.com/?p=98950 Having a high blood tumor mutational burden was associated with a significant improvement in response and a trend toward improvement in survival outcomes.]]> https://www.oncologynurseadvisor.com/home/cancer-types/gastrointestinal-cancer/esophageal-squamous-cell-carcinoma-tislelizumab-second-line-prolongs-survival/ Tue, 10 May 2022 13:45:00 +0000 https://www.oncologynurseadvisor.com/?p=98946 Tislelizumab reduced the risk of death by 30%, when compared with chemotherapy. ]]> https://www.oncologynurseadvisor.com/home/cancer-types/general-oncology/cancer-vitamin-d-omega-3s-exercise-reduce-risk-older-adults/ Tue, 10 May 2022 13:30:00 +0000 https://www.oncologynurseadvisor.com/?p=98880 Researchers observed a 61% reduction in the risk of invasive cancer among patients who completed a home exercise program and took vitamin D3 and omega-3 fatty acids daily. ]]>